Literature DB >> 10073292

Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome.

C J Peters1, G L Simpson, H Levy.   

Abstract

Hantaviruses chronically infect rodents without apparent disease, but when they are spread by aerosolized excreta to humans, two major clinical syndromes result: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Both diseases appear to be immunopathologic, and inflammatory mediators are important in causing the clinical manifestations. In HPS, T cells act on heavily infected pulmonary endothelium, and it is suspected that gamma interferon and tumor necrosis factor are major agents of a reversible increase in vascular permeability that leads to severe, noncardiogenic pulmonary edema. HFRS has prominent systemic manifestations. The retroperitoneum is a major site of vascular leak and the kidneys suffer tubular necrosis. Both syndromes are accompanied by myocardial depression and hypotension or shock. HFRS is primarily a Eurasian disease, whereas HPS appears to be confined to the Americas; these geographic distinctions correlate with the phylogenies of the rodent hosts and the viruses that coevolved with them.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073292     DOI: 10.1146/annurev.med.50.1.531

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  81 in total

1.  Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice.

Authors:  Dominic Wichmann; Hermann-Josef Gröne; Michael Frese; Jovan Pavlovic; Bärbel Anheier; Otto Haller; Hans-Dieter Klenk; Heinz Feldmann
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

2.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

Review 3.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

4.  Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers.

Authors:  Rong Xu; Xiao Yan Yang; Dao Feng Yang; Chang Yong Zou; Pei Li Gong; Fan Dian Zeng
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

5.  Hantavirus pulmonary syndrome in Manitoba.

Authors:  L Robbin Lindsay; M A Drebot; E Weiss; H Artsob
Journal:  Can J Infect Dis       Date:  2001-05

6.  Sin nombre virus (SNV) Ig isotype antibody response during acute and convalescent phases of hantavirus pulmonary syndrome.

Authors:  P Bostik; J Winter; T G Ksiazek; P E Rollin; F Villinger; S R Zaki; C J Peters; A A Ansari
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

7.  Renal artery embolization of perirenal hematoma in hemorrhagic fever with renal syndrome: a case report.

Authors:  Hee Seok Choi; Yong Seok Lee; Jae Cheol Hwang; Ji Hyon Lim; Kyung Soo Kim; Yup Yoon
Journal:  Korean J Radiol       Date:  2007 Jul-Aug       Impact factor: 3.500

8.  Hantavirus infection with marked sinus bradycardia, Taiwan.

Authors:  Yuan-Hong Liu; Jyh-Hsiung Huang; Po-Ren Hsueh; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-06       Impact factor: 6.883

9.  Genetic characterization of hantaviruses transmitted by the Korean field mouse (Apodemus peninsulae), Far East Russia.

Authors:  Kumari Lokugamage; Hiroaki Kariwa; Daisuke Hayasaka; Bai Zhong Cui; Takuya Iwasaki; Nandadeva Lokugamage; Leonid I Ivanov; Vladimir I Volkov; Vladimir A Demenev; Raisa Slonova; Galina Kompanets; Tatyana Kushnaryova; Takeshi Kurata; Kenji Maeda; Koichi Araki; Tetsuya Mizutani; Kumiko Yoshimatsu; Jiro Arikawa; Ikuo Takashima
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein.

Authors:  Jie Yang; Rui Chen; Junxia Wei; Fanglin Zhang; Yong Zhang; Lintao Jia; Yan Yan; Wen Luo; Yunxin Cao; Libo Yao; Jifeng Sun; Zhikai Xu; Angang Yang
Journal:  Appl Microbiol Biotechnol       Date:  2009-12-10       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.